The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 03, 2016
Filed:
Oct. 10, 2014
Niklas Heine, Biberach an der Riss, DE;
Christian Eickmeier, Mittelbiberach, DE;
Marco Ferrera, San Donato Milanese, IT;
Riccardo Giovannini, Verona, IT;
Holger Rosenbrock, Mittelbiberach, DE;
Gerhard Schaenzle, Biberach an der Riss, DE;
Niklas Heine, Biberach an der Riss, DE;
Christian Eickmeier, Mittelbiberach, DE;
Marco Ferrera, San Donato Milanese, IT;
Riccardo Giovannini, Verona, IT;
Holger Rosenbrock, Mittelbiberach, DE;
Gerhard Schaenzle, Biberach an der Riss, DE;
Boehringer Ingelheim International GmbH, Ingelheim am Rhein, DE;
Abstract
The invention relates to novel 6-Cycloalkyl-pyrazolopyrimidinones according to formula (I). wherein Ris a 5 or 6 membered aromatic heteroaryl-group, Ris an optional substituent, D is optionally substituted cyclopentyl, cyclohexyl, tetrahydrofuranyl, tetrahydropyranyl or 2-, 3- or 4-pyridyl, m=1 or 2 and n is 0, 1 or 2. The new compounds are for use as the active entity of medicaments or for the manufacture of medicaments respectively, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. Such conditions may for example be associated with Alzheimer's disease, schizophrenia and other diseases. The new compounds are also for example for the manufacture of medicaments and/or for use in the treatment of these diseases, in particular for cognitive impairment associated with such disease. The compounds of the invention show PDE9 inhibiting properties.